PapersFlow Research Brief
Vascular Malformations and Hemangiomas
Research Guide
What is Vascular Malformations and Hemangiomas?
Vascular malformations and hemangiomas are distinct categories of vascular anomalies in infants and children, where hemangiomas represent proliferative tumors that grow rapidly after birth and involute over time, while vascular malformations consist of structural abnormalities of blood or lymphatic vessels present at birth that persist and expand proportionally with growth.
Analysis of 49 vascular lesion specimens distinguished hemangiomas, characterized by cellular proliferation, from vascular malformations based on endothelial and pericyte characteristics (Mulliken and Glowacki, 1982). The field encompasses 56,394 published works focused on classification, diagnosis, and treatment of these anomalies, including use of propranolol and sirolimus. Key syndromes addressed include Sturge-Weber syndrome, PHACE syndrome, and Klippel-Trenaunay syndrome, with associated genetic mutations such as PIK3CA and RASA1.
Topic Hierarchy
Research Sub-Topics
Infantile Hemangiomas Propranolol Treatment
This sub-topic evaluates beta-blocker propranolol's efficacy, dosing, and mechanisms in regressing proliferating hemangiomas. Researchers study cardiovascular safety, rebound growth, and ulceration healing.
PIK3CA Mutations in Vascular Malformations
Focuses on somatic PIK3CA hotspot mutations driving overgrowth in PROS syndromes like CLOVES. Studies include targeted mTOR inhibitors and genotype-phenotype correlations.
Lymphatic Malformations Sirolimus Therapy
Examines mTOR inhibitor sirolimus for macrocystic and microcystic lymphatic anomalies unresponsive to sclerotherapy. Researchers assess volumetrics, complication rates, and combination regimens.
Sturge-Weber Syndrome GNAQ Mutations
Investigates somatic GNAQ R183Q mutations causing leptomeningeal angiomatosis and port-wine stains. Studies cover neuroimaging biomarkers, epileptogenesis, and glaucoma risks.
PHACE Syndrome Vascular Phenotypes
This area details cerebrovascular anomalies, aortic coarctation, and sternal defects in PHACE association. Researchers classify anomalies via MRA and stratify stroke risks.
Why It Matters
Accurate classification of vascular malformations and hemangiomas guides targeted treatments that prevent functional impairment or disfigurement in infants. Propranolol inhibits growth of severe infantile capillary hemangiomas in children, as observed in 11 cases where it impaired vital or sensory functions (Léauté‐Labrèze et al., 2008). Earlier interferon alfa-2a induced regression in life-threatening, corticosteroid-resistant hemangiomas (Ezekowitz et al., 1992). Somatic GNAQ mutations cause Sturge-Weber syndrome and port-wine stains, enabling precise diagnosis (Shirley et al., 2013). The International Society for the Study of Vascular Anomalies recommends standardized nomenclature to avoid misdiagnosis, which affects evaluation and management across disciplines (Wassef et al., 2015).
Reading Guide
Where to Start
"Hemangiomas and Vascular Malformations in Infants and Children" by Mulliken and Glowacki (1982), as it provides the foundational histological distinction between these lesions based on 49 specimens, essential for understanding all subsequent classification and treatment advances.
Key Papers Explained
Mulliken and Glowacki (1982) established the core distinction between hemangiomas and malformations in "Hemangiomas and Vascular Malformations in Infants and Children." Léauté‐Labrèze et al. (2008) built on this in "Propranolol for Severe Hemangiomas of Infancy" by introducing a pharmacologic treatment that halts proliferation. Ezekowitz et al. (1992) preceded with interferon in "Interferon Alfa-2a Therapy for Life-Threatening Hemangiomas of Infancy." Wassef et al. (2015) standardized nomenclature in "Vascular Anomalies Classification: Recommendations From the International Society for the Study of Vascular Anomalies," integrating prior work. Shirley et al. (2013) added genetics in "Sturge–Weber Syndrome and Port-Wine Stains Caused by Somatic Mutation in GNAQ."
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Current classification relies on ISSVA recommendations (Wassef et al., 2015), with genetic insights into PIK3CA and RASA1 mutations for syndromes like Klippel-Trenaunay. Sirolimus targets mTOR pathways in lymphatic malformations. No recent preprints available, so focus remains on refining propranolol protocols and mutation-specific therapies from established papers.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Hemangiomas and Vascular Malformations in Infants and Children | 1982 | Plastic & Reconstructi... | 3.3K | ✕ |
| 2 | Propranolol for Severe Hemangiomas of Infancy | 2008 | New England Journal of... | 2.3K | ✕ |
| 3 | HEMANGIOPERICYTOMA A VASCULAR TUMOR FEATURING ZIMMERMANNʼS PER... | 1942 | Annals of Surgery | 1.4K | ✕ |
| 4 | Lymphangiogenesis: Molecular Mechanisms and Future Promise | 2010 | Cell | 1.4K | ✓ |
| 5 | Vascular Anomalies Classification: Recommendations From the In... | 2015 | PEDIATRICS | 1.3K | ✕ |
| 6 | Recurrent BRAF mutations in Langerhans cell histiocytosis | 2010 | Blood | 1.2K | ✕ |
| 7 | Angiosarcomas Express Mixed Endothelial Phenotypes of Blood an... | 1999 | American Journal Of Pa... | 1.1K | ✓ |
| 8 | Interferon Alfa-2a Therapy for Life-Threatening Hemangiomas of... | 1992 | New England Journal of... | 1.1K | ✓ |
| 9 | Sturge–Weber Syndrome and Port-Wine Stains Caused by Somatic M... | 2013 | New England Journal of... | 1.1K | ✓ |
| 10 | Adjuvant chemotherapy for localised resectable soft-tissue sar... | 1997 | The Lancet | 1.0K | ✕ |
Frequently Asked Questions
What distinguishes hemangiomas from vascular malformations?
Hemangiomas are proliferative lesions with rapid postnatal growth followed by involution, driven by endothelial cell hyperplasia. Vascular malformations are congenital structural anomalies that grow proportionally with the child and do not involute. This distinction emerged from analysis of 49 specimens showing differences in cellular characteristics (Mulliken and Glowacki, 1982).
How does propranolol treat infantile hemangiomas?
Propranolol inhibits the growth of severe infantile capillary hemangiomas that impair vital or sensory functions or cause disfigurement. It was effective in 11 children despite their self-limited course. The treatment provides an alternative to prior options like interferon (Léauté‐Labrèze et al., 2008).
What is the genetic basis of Sturge-Weber syndrome?
Sturge-Weber syndrome and port-wine stains result from somatic activating mutations in GNAQ. This confirms a prior hypothesis linking the gene to these vascular anomalies. The mutation was identified through genomic analysis of affected tissues (Shirley et al., 2013).
Why is accurate classification of vascular anomalies important?
Vascular anomalies range from simple birthmarks to life-threatening conditions, and misdiagnosis is common due to incorrect nomenclature. Precise classification ensures appropriate multidisciplinary evaluation and management. The International Society for the Study of Vascular Anomalies issued recommendations to standardize terms (Wassef et al., 2015).
What prior treatments were used for life-threatening hemangiomas?
Interferon alfa-2a induced early regression in life-threatening hemangiomas of infancy resistant to corticosteroids. It was tested in cases threatening vital functions. Propranolol later emerged as a safer option (Ezekowitz et al., 1992).
Open Research Questions
- ? What are the precise molecular pathways driving proliferation in hemangiomas beyond initial classification?
- ? How do somatic mutations like GNAQ in Sturge-Weber syndrome interact with vessel development?
- ? What long-term outcomes compare propranolol versus sirolimus in complex vascular malformations?
- ? How can imaging and genetic testing refine classification of lymphatic malformations?
- ? What mechanisms underlie resistance to beta-blockers in persistent hemangiomas?
Recent Trends
The field includes 56,394 works with no specified 5-year growth rate.
Established treatments like propranolol (Léauté‐Labrèze et al., 2008) and genetic findings such as GNAQ mutations (Shirley et al., 2013) remain central, as no recent preprints or news coverage indicate shifts.
ISSVA classification standards from 2015 (Wassef et al.) continue to guide diagnosis.
Research Vascular Malformations and Hemangiomas with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Vascular Malformations and Hemangiomas with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers